-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 5, 1981, the US Centers for Disease Control and Prevention published a case report of 5 AIDS patients, which was the first official record of AIDS in the world
To end AIDS, prevention is one of the focuses of scientists
In the current situation where HIV prevention vaccines have not been successfully developed, pre-exposure prophylaxis (PrEP), mainly antiretroviral therapy (ART), is a means to slow down the AIDS epidemic.
In this study, the researchers first evaluated the ability of Leronlimab to inhibit the spread of HIV virus between cells in an in vitro diffusion test.
Subsequently, the research team evaluated whether Leronlimab can be used as PrEP to withstand repeated low-dose intrarectal (intrarectal, IR) SIV virus invasion.
The test results showed that all animals showed good tolerance to Leronlimab without adverse clinical reactions, which confirmed its high safety reported in multiple previous clinical trials
The study mentioned at the end that Leronlimab can be administered subcutaneously at home, which is more advantageous than other intramuscular injections that need to be administered in the clinic
In view of the fact that the CCR5 Δ32/Δ32 phenotype can resist HIV infection without threatening life, and the safety of Leronlimab has also been further verified.
Reference materials:
[1]https://